Active, not recruitingPhase 1NCT05828589
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BeOne Medicines
- Principal Investigator
- Study DirectorBeOne Medicines
- Intervention
- BGB-21447(drug)
- Enrollment
- 112 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (28)
- Sibley Memorial Hospital Johns Hopkins Medicine, Washington D.C., District of Columbia, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Mission Cancer and Blood, Waukee, Iowa, United States
- Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
- Nyu Langone Health Perlmutter Cancer Center At Nyu Langone Hospital Long Island, Mineola, New York, United States
- Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health, New York, New York, United States
- Avera Cancer Institute, Sioux Falls, South Dakota, United States
- Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
- Pindara Private Hospital, Benowa, Queensland, Australia
- Mater Cancer Care Centre, South Brisbane, Queensland, Australia
- Monash Health, Clayton, Victoria, Australia
- Linear Clinical Research, Nedlands, Western Australia, Australia
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- Fujian Cancer Hospital, Fuzhou, Fujian, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05828589 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.